Program
BMS-986310
Also written as “ONO-4578”.
Its studies are mostly in Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by 2 companies.
Drug pageBMS-986310: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ono Pharmaceuticalits history only | 54 open or running | phase 3since Sep 9, 2026 | Mar 17, 2017 | Feb 15, 2028phase 2 · NCT06948448 |
| Bristol-Myers Squibb | 10 open or running | phase 1since Aug 30, 2018 | Aug 30, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 30, 2018First study: phase 1 study in Advanced CancerFirst studyNCT03661632 · 27 enrolled · United States, Belgium, Canada
TargetBeta
“An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), ”NCIt, by rule
Other programs on PTGER4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| EP4 Receptor Antagonist YY001rule | chongqing-claruvis-pharmaceutical-co-ltd | phase 3 | 6 |
| EP2/EP4/DP1 Antagonist OKN4395rule | epkin | phase 1 | 1 |
Studies
The one study Bristol-Myers Squibb leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03661632Advanced Cancer · United States, Belgium, Canada | 1 | Completed | Nov 11, 2019 | 27 |
How it is read
Names in the registry
- “ONO-4578”, 5 entries
- “BMS-986310”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.